Drugs / RTN-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07142356 | Oct 2025 → Oct 2026 expected | hypertensive disorder | Retension Pharmaceuticals. Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142356 ↗ |
| Action | Inhibit | “A potent and selective PDE5 inhibitor.” NCT07142356 ↗ |
| Route | Oral | “RTN-001 will be administered orally.” NCT07142356 ↗ |